Nanexa AB (DE:40M)
FRANKFURT:40M
Want to see DE:40M full AI Analyst Report?
40M Stock Chart & Stats
€0.25
>-€0.01(-2.14%)
At close: 4:00 PM EST
€0.25
>-€0.01(-2.14%)
Day’s Range― - ―
52-Week Range€0.12 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€63.75M
Enterprise Value€557.14M
Total Cash (Recent Filing)€73.02M
Total Debt (Recent Filing)€987.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding191,036,530
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-26.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€10.36M
Bulls Say, Bears Say
Bulls Say
Partnership- And Licensing-driven Business ModelA licensing/partnership model centered on the PharmaShell platform creates scalable, asset-lite revenue potential via upfronts, R&D fees, milestones and royalties. This reduces capital intensity versus full commercialization and aligns incentives with pharma partners, supporting durable revenue levers if deals close.
Conservatively Financed Balance Sheet With Very Low LeverageVery low debt and growing equity provide meaningful financial flexibility for a development-stage pharma firm. This reduces default risk, lowers interest burden, and preserves optionality to fund R&D or structure deal-based development without immediate dilutive financing, a durable strength during long cycles.
Trend Toward Positive Operating Cash FlowA shift to slightly positive operating cash flow signals operational improvement and progress toward self-sustaining activities. For a licensing-focused company, improving operating cash generation can reduce near-term financing needs and increase negotiating leverage with partners over the medium term.
Bears Say
Deep Negative Free Cash Flow And Ongoing Cash BurnLarge negative free cash flow indicates sustained cash outflows for development that exceed operating receipts, creating ongoing funding requirements. Persistent FCF deficits raise dilution or debt risks, hinder long-term investment flexibility, and make the business dependent on partner payments or new financing to sustain operations.
Persistent Unprofitability And Weak MarginsA deep negative net margin and continued operating losses reflect that the platform has yet to translate into profitable commercial revenues. This structural unprofitability increases reliance on external funding and requires successful, timely partnerships or product launches to achieve sustainable margins over the medium term.
No Disclosed Signed Partnerships Or Product RevenuesThe absence of disclosed signed partnerships or product revenues raises execution and revenue-visibility risk for a licensing-focused model. Without confirmed deals, future cash flows and milestone timing are uncertain, lengthening the path to recurring royalties and increasing dependence on speculative development outcomes.
Nanexa AB News
40M FAQ
What was Nanexa AB’s price range in the past 12 months?
Nanexa AB lowest stock price was €0.12 and its highest was €0.43 in the past 12 months.
What is Nanexa AB’s market cap?
Nanexa AB’s market cap is €63.75M.
When is Nanexa AB’s upcoming earnings report date?
Nanexa AB’s upcoming earnings report date is Aug 27, 2026 which is in 94 days.
How were Nanexa AB’s earnings last quarter?
Nanexa AB released its earnings results on Apr 29, 2026. The company reported -€0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.008.
Is Nanexa AB overvalued?
According to Wall Street analysts Nanexa AB’s price is currently Overvalued.
Does Nanexa AB pay dividends?
Nanexa AB does not currently pay dividends.
What is Nanexa AB’s EPS estimate?
Nanexa AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanexa AB have?
Nanexa AB has 191,036,530 shares outstanding.
What happened to Nanexa AB’s price movement after its last earnings report?
Nanexa AB reported an EPS of -€0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.231%.
Which hedge fund is a major shareholder of Nanexa AB?
Currently, no hedge funds are holding shares in DE:40M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanexa AB
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Vivesto AB
―
Klaria Pharma Holding AB
―
Enzymatica AB
―
Enorama Pharma AB
―